share_log

Veru shares are trading higher after the company announced it received FDA agreement to advance VERU-111 into Phase 3 study in hospitalized COVID-19 patients at high risk for acute respiratory distres

Veru shares are trading higher after the company announced it received FDA agreement to advance VERU-111 into Phase 3 study in hospitalized COVID-19 patients at high risk for acute respiratory distres

在該公司宣佈收到食品和藥物管理局的協議，將VERU-111提前到第三階段研究後，VERU的股價上漲，該研究針對新冠肺炎住院的急性呼吸窘迫高危患者。
Benzinga ·  2021/03/01 22:05

Veru shares are trading higher after the company announced it received FDA agreement to advance VERU-111 into Phase 3 study in hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome.

在該公司宣佈收到食品和藥物管理局的協議，將VERU-111提前進入第三階段研究後，VERU的股價正在上漲。VERU-111是住院的新冠肺炎患者中急性呼吸窘迫綜合徵的高危患者。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論